Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did anyone post yesterday that David Einhorn of Greenlight Capital thinks AAPL could be a trillion dollar company?
Manny
VHC,
From IV:
"Lighening Round" - Cramer is bullish on VHC ....
. . . . on a speculative basis.
Listen to his words on the video:
http://www.cnbc.com/id/47452236
Did anyone hear the brilliant phrase the Steve Tyler said,I think it was to Phillip?
"Get used to it,because you never will".
Wow.
I voted 25 times for Joshua,who I think is the most versatile singer ever on American Idol.
I think that Joshua is one of the best singers I have ever heard.
He was brilliant on the "No more pain" song.Jessica was very good,and Phillip was only good in his last song as far as I am concerned.
The question I ask myself is,who's concert would I want to go to.
There is no question that it would be Joshua's concert.
I think Joshua and Jessica should be the top two,but all the girls and women will probably put Phillip through.
Manny
VHC,
From IV:
Cowen raises to $55 target - Raises Patent Value to $3.5B
$VHC - Cowen raising price target to $55, raising patent value to 3.5 Billion , believe other companies will settle.
Manny
VHC,
From IV:
Cowen raises to $55 target - Raises Patent Value to $3.5B
$VHC - Cowen raising price target to $55, raising patent value to 3.5 Billion , believe other companies will settle.
Manny
Doesn't this patent allowance news give CIGX the potential of being a takeover candidate if Anatabloc proves successful?
Manny
CIGX,
Star Scientific Announces Patent Claims for Synthesis of ar Scientific Announces Patent Claims for Synthesis of Anatabine Granted by US PTO
PR Newswire
GLEN ALLEN, Va., May 16, 2012
GLEN ALLEN, Va., May 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) announced that the U.S. Patent and Trademark Office ("PTO") issued a Notice of Allowance on May 11, 2012 to Rock Creek Pharmaceuticals, Inc., its wholly owned subsidiary, in Application No. 12/729,346, covering an improved method for the synthetic preparation of anatabine. A Notice of Allowance, issued by the PTO, is a notification that an applicant is entitled to a patent. A written patent on this application will issue in the next few months.
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
Dr. Curtis Wright, Senior Vice President and Medical Director of Rock Creek Pharmaceuticals commented, "I have been working with the problems of natural extracts and plant products for over 20 years, and I cannot overemphasize the value of having properly secured intellectual property for the synthesis and purification of compounds of interest to our company. I continue to be impressed by work done by our staff and that of our research partners in adding to the value of this company."
The allowed '346 application discloses an improved process for synthesizing anatabine that facilitates larger scale, commercial production. The method, therefore, represents an improvement over the prior art, which allowed for smaller scale production at lower yields, and in a manner that limited the ability to scale-up the process. The company, through Rock Creek, is also pursuing several additional patent applications covering anatabine salts, dietary formulations containing anatabine, and methods of administering anatabine for the nutritional management of disorders associated with unhealthy levels of inflammation.
Paul L. Perito, Rock Creek's Chairman and CEO stated: "We cannot overstate the significance of these US PTO approved patent claims since the anatabine in our dietary supplement, Anatabloc®, is made utilizing the process covered by these claims. Further, all of our ongoing clinical trials utilize anatabine that has been manufactured utilizing this protected process. Given our focus on this unique alkaloid over the last several years, and the role that we believe it can play in assisting in maintaining healthy levels of inflammation, having an available source of anatabine that is protected by a patent is an important step forward for Star Scientific and its shareholders. In a parallel fashion, we continue to pursue a number of related patent applications for anatabine, anatabine citrate, and its isomers and salts that we believe will strengthen and expand our intellectual property rights. Our existing and expanding patent portfolio constitutes the crown jewels of our company. Those treasured assets, merit our continuing commitment to establish, maintain, and defend our intellectual property and existing patents from potential infringers."
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
Contact:Talhia T. TuckVice President, Communications and Investor RelationsStar Scientific, Inc. (301) 654-8300ttuck@starscientific.com
SOURCE Star Scientific, Inc.
CIGX,
Star Scientific Announces Patent Claims for Synthesis of ar Scientific Announces Patent Claims for Synthesis of Anatabine Granted by US PTO
PR Newswire
GLEN ALLEN, Va., May 16, 2012
GLEN ALLEN, Va., May 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) announced that the U.S. Patent and Trademark Office ("PTO") issued a Notice of Allowance on May 11, 2012 to Rock Creek Pharmaceuticals, Inc., its wholly owned subsidiary, in Application No. 12/729,346, covering an improved method for the synthetic preparation of anatabine. A Notice of Allowance, issued by the PTO, is a notification that an applicant is entitled to a patent. A written patent on this application will issue in the next few months.
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
Dr. Curtis Wright, Senior Vice President and Medical Director of Rock Creek Pharmaceuticals commented, "I have been working with the problems of natural extracts and plant products for over 20 years, and I cannot overemphasize the value of having properly secured intellectual property for the synthesis and purification of compounds of interest to our company. I continue to be impressed by work done by our staff and that of our research partners in adding to the value of this company."
The allowed '346 application discloses an improved process for synthesizing anatabine that facilitates larger scale, commercial production. The method, therefore, represents an improvement over the prior art, which allowed for smaller scale production at lower yields, and in a manner that limited the ability to scale-up the process. The company, through Rock Creek, is also pursuing several additional patent applications covering anatabine salts, dietary formulations containing anatabine, and methods of administering anatabine for the nutritional management of disorders associated with unhealthy levels of inflammation.
Paul L. Perito, Rock Creek's Chairman and CEO stated: "We cannot overstate the significance of these US PTO approved patent claims since the anatabine in our dietary supplement, Anatabloc®, is made utilizing the process covered by these claims. Further, all of our ongoing clinical trials utilize anatabine that has been manufactured utilizing this protected process. Given our focus on this unique alkaloid over the last several years, and the role that we believe it can play in assisting in maintaining healthy levels of inflammation, having an available source of anatabine that is protected by a patent is an important step forward for Star Scientific and its shareholders. In a parallel fashion, we continue to pursue a number of related patent applications for anatabine, anatabine citrate, and its isomers and salts that we believe will strengthen and expand our intellectual property rights. Our existing and expanding patent portfolio constitutes the crown jewels of our company. Those treasured assets, merit our continuing commitment to establish, maintain, and defend our intellectual property and existing patents from potential infringers."
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
Contact:Talhia T. TuckVice President, Communications and Investor RelationsStar Scientific, Inc. (301) 654-8300ttuck@starscientific.com
SOURCE Star Scientific, Inc.
TSPT,
Cowen starts TSPT at outperform.
Manny
Cowen starts TSPT at outperform.
Manny
SCKT,
Medanets Oy Standardizes on Socket SoMo(R) Handheld Computers for Capturing Vital Signs at the Point of Care
Socket Mobile, Inc. (NASDAQ: SCKT), an innovative provider of mobile productivity solutions, today announced that Medanets Oy -- a company in Finland that specializes in designing wireless products for healthcare -- has standardized the Socket SoMo medical PDA as its device of choice for their mobile point-of-care solution, Medanets ABS.
The Medanets ABS solution features the antimicrobial Socket SoMo medical PDA enhanced with the portable Socket RFID/barcode reader. The SoMo connects wirelessly via Bluetooth® to medical devices to quickly capture vital signs. Nurses verify the measurements, add notes as needed, then send the data wirelessly over the hospital's Wi-Fi® network to automatically update a patient's electronic health record (EHR). This enables nurses to increase the efficiency and accuracy of documentation and gives physicians instant access to real-time patient information -- all of which translates into smarter decision making and improved patient care.
"With the SoMo, the everyday measurements that nurses make in the ward need minimal time compared to the earlier system of manual documentation, and the information is entered into the hospital EHR system without delays," said Hannu Kotipalo, technical manager at Medanets Oy. "This means that nurses can spend more time on direct patient care."
Several hospitals in Finland have already deployed the solution, including Tampere University Hospital, Hämeenlinna Central Hospital, and Savonlinna Central Hospital, with several more piloting. By enabling nurses to automatically capture, validate, and submit vitals right from bedside, the Medanets ABS solution has saved each hospital 40-60 hours of nursing paperwork per month per inpatient ward, depending on the size of the ward and number of filings per day. Enhanced with the Socket RFID/barcode reader, the SoMo has also increased patient safety, allowing nurses to scan patient wristbands prior to entering data, ensuring the correct data is being filed for the correct patient.
"Tens of thousands of SoMos are currently in use with healthcare applications worldwide," said Vince Coli, senior product manager of handheld computing products at Socket Mobile. "The wireless functionality and customizability make it ideal for healthcare facilities. With powerful applications like Medanets ABS, the SoMo enables nurses to connect to Bluetooth medical devices, communicate potentially life-saving medical information in real-time, and add options like Auto ID to increase patient safety and efficiency."
For more information about the Socket SoMo handheld device, visit the Socket Mobile Healthcare Solutions website.
About Medanets Oy
Medanets Oy, located in Kempele, Finland, specializes in designing wireless system products for healthcare. Medanets Oy's product is a Point Of Care recording system called Medanets ABS. With it nursing staff can record, save, and browse the results of patient measurements, all at bedside using a lightweight PDA. Measurement data is transferred into the information system via a wireless network, either automatically or with one entry. The information is immediately available to all system users. Medanets Oy is deeply rooted in Oulu's know-how in wireless technology, which is recognized and appreciated worldwide. For more information visit www.medanets.com
About Socket Mobile
With 20 years of experience in the Automatic Identification and Data Capture (AIDC) market, Socket makes mobile computing and productivity work. The company offers a family of handheld computers and an extensive portfolio of AIDC peripherals specifically designed to increase productivity and drive operational efficiencies in healthcare, hospitality and other business mobility deployments. The company also offers OEM solutions for the mobile device market. Socket is headquartered in Newark, Calif. and can be reached at 510-933-3000 or www.socketmobile.com. Follow Socket Mobile on Twitter @socketmobile and subscribe to sockettalk.socketmobile.com, the company's official blog.
Socket and SoMo are trademarks or registered trademarks of Socket Mobile. All other trademarks and trade names contained herein may be those of their respective owners.
© 2012, Socket Mobile, Inc. All rights reserved.
Post Unavailable
Additional Information
I see this 50,000 share purchase by a director at average .5622 on 5/9 and 5/10 wasn't posted.
http://www.secform4.com/insider-trading/1160308.htm
Manny
MSEH,
Thanks for the explanation.
I just added some at .17 to reduce my average.
Manny
MSEH,
Can someone explain to me how the Director ended up with 1,009,584 shares,and not 1,197,054 after buying those 125,000 shares?
http://www.secform4.com/insider-trading/1425597.htm
Manny
Found on another MB,
$INTC reiterated its Q2 and 2012 guidance and refuted $CSCO cautious enterprise remarks
Manny
Hey,
With my memory for names,you are lucky I didn't call him Bovine.
LOL,
Manny
Hollie is out.
Jimmie Bevino said that both Joshua and Jessica will get record contracts.
Jessica wants to win really bad.I don't think it will matter who is number one or two.They will both be successful.
Manny
Found this post on Silicon Investor by a really smart guy called robert furman.
He thinks the JPM loss is B.S.
What do you think?
"JPM's hedge with surplus funds was a march short on European corporate debt.
JPM thought corporate debt would get clipped along with sovereign debt.
Earnings were solid and corporate debt went the wrong way leaving JPM on the wrong side of shorting corporate bonds after earnings proved Euro corporate profits are intact.
So make a BS announcement about an unrealized loss that was compared on a mark to market comp and hope to push the market down.
I'm thinking this has the stuff of an island reversal tomorrow.
Banks do NOT lose on credit swaps unless the counter party goes broke.
This market needs to get over the fear mongering about interest rate derivatives, that 99% of the people do not know about - that's why it is such fodder for rumors.They've been around for ever - they are not big risks to the banks.
Put it this way if a bank has a customer with excess fund and wants to make a higher yield.They take that money and sell a commitment to an lender that wants to lock in his cost on that money.
The bank makes a spread - in car dealers case it it as low as 150 basis points to say 275 points.
When the libor you charge off of is 1.99% and you make another 175 points on it - the only way a bank loses is if the borrower goes broke and defaults.
If there is a risk in that - a credit swap is never offered.
2008 made that reality very clear.
Interest rate swaps do Not exceed time duration of 5 years max and they are offered at a lower spread if the bank retains a 3 year early out clause.
I'm buying the open, on a bet it is an island reversal set up.
UUHHHH scare monger # 2.
Csco said that government purchases might be impacted in the future with Austerity cuts causing push outs.
Nah really - now that"s news .
Listen to any defense contractors webcast lately?
The big budgets of Big G are dwindling in a forward guidance basis.
Csco is a huge provider of government data base equipment.
I suspect it is a head wind but I think the server farms that Intel has proven are alive and well - will still be very solid high margin business.
JMHO
Lets invest not create fear mongering panic.
I agree with your read.
I'm thinking the low @ 10:35 EST tomorrow may well be a great buy.Buy it, shiver like a pup passing a peach pit and hold it through the volatility of next week ends with a posibility of post expiration adjustment through the next tuesday.
If sold puts pushes people to buy stock on Saturday (expiration next week) they'll sell them on monday/tuesday.
Then hold onto your hat.
Bob"
I think Joshua was really great,but Jessica sang like she was pleading for her life.
It is amazing that she was able to control her voice with all that pressure she put on herself.
She is a winner.
Manny
I was going to post,"Joshua Ledet,enough said".
Then I heard Jessica,and I have never seen anyone pour their heart out on a song like she did.(Joshua was pretty great also on his second song)
Jessica's almost being eliminated from American Idol made her the star she has become.She really wants to win.
I think Jessica and Joshua are way above the other 2.
Hollie will probably go,as the judges made sure to put Hollie down,as they figured Phillip would probably be voted through.
They wanted Jessica to stay.
That last song should guarantee Jessica's place in the top 3.
Manny
SQNM news,
Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's MaterniT21™ PL...
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). The test detects certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal anomalies.
The agreement ensures that the 2.2 million members of the Coventry First Health PPO network will have coverage for Sequenom CMM's MaterniT21 PLUS testing service, with access to more than 5,000 hospitals and 500,000 health professionals in all 50 states, including the District of Columbia and Puerto Rico.
"The coverage of the Sequenom CMM MaterniT21 PLUS LDT by the Coventry network is an important milestone, as it will ensure that doctors who are Coventry members will have access to this important testing service to help provide expectant families with important information about their pregnancy through a noninvasive, highly accurate technology," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.
The MaterniT21 PLUS LDT is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation. In the United States, there are an estimated 750,000 high-risk pregnancies each year. Results of the MaterniT21 PLUS LDT delivered to ordering physicians will include the presence of trisomy 21, 18 or 13 for patients at increased risk of one of these anomalies. The MaterniT21 PLUS test is available through Sequenom CMM as a testing service to physicians. To learn more, please visit Sequenomcmm.com.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory-developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists, maternal fetal medicine specialists, ophthalmologists and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.
SQNM news,
Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's MaterniT21™ PL...
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). The test detects certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal anomalies.
The agreement ensures that the 2.2 million members of the Coventry First Health PPO network will have coverage for Sequenom CMM's MaterniT21 PLUS testing service, with access to more than 5,000 hospitals and 500,000 health professionals in all 50 states, including the District of Columbia and Puerto Rico.
"The coverage of the Sequenom CMM MaterniT21 PLUS LDT by the Coventry network is an important milestone, as it will ensure that doctors who are Coventry members will have access to this important testing service to help provide expectant families with important information about their pregnancy through a noninvasive, highly accurate technology," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.
The MaterniT21 PLUS LDT is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation. In the United States, there are an estimated 750,000 high-risk pregnancies each year. Results of the MaterniT21 PLUS LDT delivered to ordering physicians will include the presence of trisomy 21, 18 or 13 for patients at increased risk of one of these anomalies. The MaterniT21 PLUS test is available through Sequenom CMM as a testing service to physicians. To learn more, please visit Sequenomcmm.com.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory-developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists, maternal fetal medicine specialists, ophthalmologists and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.
SQNM,
In a 13G filing,SAC Capital Mgmt.owns 5.4% of SQNM.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8249365
Doesn't look like they held much before this filing:
http://finance.yahoo.com/q/mh?s=SQNM+Major+Holders
Manny
SQNM,
In a 13G filing,SAC Capital Mgmt.owns 5.4% of SQNM.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8249365
Manny
IBIO,
Broad Patent Protection Granted for iBio Immunomodulator
PR Newswire
NEWARK, Del., May 8, 2012
NEWARK, Del., May 8, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator™ platform. The new patent, which provides broad protection of the platform, is US Patent 8,173,408, entitled "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides."
(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )
The iBioModulator platform has been shown to significantly modify the immune response to a vaccine in two important ways. It increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer). It also extends the duration of the immune response. These results demonstrate that the use of the iBioModulator platform can lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to provide better immune response and longer-term protection without booster inoculations adds significant value to a vaccine by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.
"The iBioModulator is another platform, separate and independent from our plant-based biologics technology," said Robert B. Kay, iBio's Chairman and CEO. "Although we recommend its use together with our iBioLaunch platform to achieve maximum efficiency in producing the fused protein, the iBioModulator is usable independently and is applicable to recombinant vaccines made with any system. We expect strong interest in its use."
Efficacy studies in animals have confirmed the superior performance of certain iBioModulator-based vaccines, and ongoing tests will provide additional data about the further extent to which prolonged immunity is conferred by the iBioModulator technology. On the strength of results obtained to date, iBio has broadened its commercial program to include additional vaccine applications for preclinical evaluation.
Among the positive tests completed to demonstrate the ability of the iBioModulator platform to improve the performance of vaccines are the following:
* An iBioModulator-Pfs 25 antigen malaria vaccine candidate in advanced pre-IND testing elicited transmission blocking activity at lower doses and for a longer period of time following immunization compared to a vaccine candidate containing the antigen alone.
* Therapeutic HPV (human papilloma virus) vaccine candidates constructed with iBioModulator provided superior protection from HPV-16 E7-induced tumors and extended survival in a mouse model when compared with vaccination with native E7 protein alone. Effective therapeutic vaccination to treat HPV-induced cancer has been a long-desired but difficult to achieve objective of healthcare professionals. The iBioModulator platform offers a new and promising approach to addressing this important goal.
* iBioModulator has been used as a fusion to express peptide or protein domain antigens in a number of other successful vaccine candidates, including those for plague and anthrax.
The iBioModulator also has been used by scientists at iBio, Inc.'s research and development partner, the Fraunhofer USA Center for Molecular Biotechnology, to improve the solubility and stability not only of recombinant vaccine antigens, but other proteins as well. Ongoing studies will include evaluation of the benefits of using the iBioModulator in the development and production of therapeutic product candidates.
iBio plans to offer the benefits of the iBioModulator platform to collaborators and licensees of product candidates initially developed by iBio and also through licenses for products developed independently by or for licensees. Features of vaccines utilizing the iBioModulator platform such as those already observed in the animal studies should enable licensees to enjoy a stronger competitive position in worldwide vaccine markets.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator™ platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Contacts:
IBIO,
Broad Patent Protection Granted for iBio Immunomodulator
PR Newswire
NEWARK, Del., May 8, 2012
NEWARK, Del., May 8, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator™ platform. The new patent, which provides broad protection of the platform, is US Patent 8,173,408, entitled "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides."
(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )
The iBioModulator platform has been shown to significantly modify the immune response to a vaccine in two important ways. It increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer). It also extends the duration of the immune response. These results demonstrate that the use of the iBioModulator platform can lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to provide better immune response and longer-term protection without booster inoculations adds significant value to a vaccine by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.
"The iBioModulator is another platform, separate and independent from our plant-based biologics technology," said Robert B. Kay, iBio's Chairman and CEO. "Although we recommend its use together with our iBioLaunch platform to achieve maximum efficiency in producing the fused protein, the iBioModulator is usable independently and is applicable to recombinant vaccines made with any system. We expect strong interest in its use."
Efficacy studies in animals have confirmed the superior performance of certain iBioModulator-based vaccines, and ongoing tests will provide additional data about the further extent to which prolonged immunity is conferred by the iBioModulator technology. On the strength of results obtained to date, iBio has broadened its commercial program to include additional vaccine applications for preclinical evaluation.
Among the positive tests completed to demonstrate the ability of the iBioModulator platform to improve the performance of vaccines are the following:
* An iBioModulator-Pfs 25 antigen malaria vaccine candidate in advanced pre-IND testing elicited transmission blocking activity at lower doses and for a longer period of time following immunization compared to a vaccine candidate containing the antigen alone.
* Therapeutic HPV (human papilloma virus) vaccine candidates constructed with iBioModulator provided superior protection from HPV-16 E7-induced tumors and extended survival in a mouse model when compared with vaccination with native E7 protein alone. Effective therapeutic vaccination to treat HPV-induced cancer has been a long-desired but difficult to achieve objective of healthcare professionals. The iBioModulator platform offers a new and promising approach to addressing this important goal.
* iBioModulator has been used as a fusion to express peptide or protein domain antigens in a number of other successful vaccine candidates, including those for plague and anthrax.
The iBioModulator also has been used by scientists at iBio, Inc.'s research and development partner, the Fraunhofer USA Center for Molecular Biotechnology, to improve the solubility and stability not only of recombinant vaccine antigens, but other proteins as well. Ongoing studies will include evaluation of the benefits of using the iBioModulator in the development and production of therapeutic product candidates.
iBio plans to offer the benefits of the iBioModulator platform to collaborators and licensees of product candidates initially developed by iBio and also through licenses for products developed independently by or for licensees. Features of vaccines utilizing the iBioModulator platform such as those already observed in the animal studies should enable licensees to enjoy a stronger competitive position in worldwide vaccine markets.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator™ platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Contacts:
Transcept Pharmaceuticals to Report First Quarter 2012 Financial Results and Host Conference Call on May 14, 2012
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 14, 2012, at 4:30 p.m. Eastern Time to discuss its first quarter 2012 financial results. The conference call will follow the release of the Transcept first quarter 2012 financial results after the close of market that day.
Conference Call Information Date: Monday, May 14, 2012 Time: 4:30 p.m. ET Dial-in (U.S.): 877-638-4558 Dial-in (International): 914-495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through July 31, 2012.
A telephone replay of the conference call will be available shortly after the conclusion of the call through May 19, 2012. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 77576088.
About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) 215-3567gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
VHC,
Kendal Larson to speak at Cowen Conference,
As per a poster on IV:
KL spoke at Cowen last year after the ASM......his Cowen talk ignited the share price rise to $41+. Last year at the ASM and at Cowen the talk revolved about the importance of the patents and their projected licensing value. This year I hope the discussion centers on how many licenses have been signed to date and how many more companies VHC is talking to. Also, a discussion of the recent Markman and it's implications would also be great. I am just starting to formulate some questions.
Best Regards,
Gare
Looks like Tang Capital likes this stock at 9 dollars.
In a filing Friday after hours,Tang capital has 9.5% stake in the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8244464
It looks like Tang bought into the recent offering at 9 dollars,because they don't show up on major holders list.
http://finance.yahoo.com/q/mh?s=TSPT+Major+Holders
Manny
TSPT,
In a filing Friday after hours,Tang capital has 9.5% stake in the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8244464
It looks like Tang bought into the recent offering at 9 dollars,because they don't show up on major holders list.
http://finance.yahoo.com/q/mh?s=TSPT+Major+Holders
Manny
TSPT,
In a filing Friday after hours,Tang capital has 9.5% stake in the company.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8244464
It looks like Tang bought into the recent offering at 9 dollars,because they don't show up on major holders list.
http://finance.yahoo.com/q/mh?s=TSPT+Major+Holders
Manny
What is Phillip doing remaining in the competition?
He should have gone.He looks like he is in pain when he sings.
The judges are already thinking that America might not pick Joshua as the American Idol,because they spoke about his getting a recording contract anyway.
We all know that many losers have done better than some winners of American Idol,so I am prepared to be disappointed.
Manny
VHC,
Another great post on IV from a long time VHC holder:
Amen. IMO this license sets the stage for VHC to be acquired at some point, just like the Seeking Alpha article talked about this morning. I have owned this stock since it listed as everything VHC has done has been leading up to a 4G license like this. The first step was the MSFT lawsuit, which was all about proving the IP was real. It did.
The next step has been to establish licensing for Release 10 LTE-A. To do this they sued the top players in key markets infringing their IP in 3G as a mechanism to force them to license for 4G. That is the whole ballgame for VHC. At the end VHC will have a licensing royalty of some percentage of a future market of 200 Billion dollars. That percentage sets the value of VHC to be acquired, which looks like the most likely exit since the company has taken no steps to build out an operating company.
VHC CEO Kendall Larsen has spent his entire career building and licensing technology. He owns or controls over 9 Million shares and if he can sell the company for $120 per share or more, personally clears a Billion Dollars. If he OK'ed this license before all the others, its because he is happy with the royalty rate - which will now be plugged into that "X% of 200 Billion" equation.
Another point is that for most of the companies VHC is suing, it wasn't a question of if they could win at trial against patents that have already been validated by a previous jury verdict and PTO reexams. They can't. It was a question of when they would pay and how much. Now that a co-defendant has thrown in the towel, any small chance a defendant had at trial just got that much smaller.
The bottom line is that the last five years of effort from this company was focused on this first license and if Larsen OK'ed this settlement, it is a VERY good thing for VHC.
VHC,
From "floydrocks" of IV,one of the sharpest and most trusted posters on IV:
Aastra Impact
The Aastra settlement is significant for a few key reasons.
1. They are paying a one time payment for past infringement and have agreed to ongoing royalty payments for future use of the patents. I expect the one time payment to be small, but that's a non-issue to me given that they have signed a deal that was agreeable to KL.
2. This shows after the Markman, the defendants are no longer united. One of the small players buckled and this is huge. It now makes all other defendants that are not Apple or Cisco potential companies that settle and license in the short-term..
3. It adds a little pressure on the USPTO with respect to the patent reexams. Clearly the patents are strong enough in Aastra's eyes that they do not see point in waiting for reexams to be finalized.
This is huge and big money will start figuring this out very soon.
VHC,
From "floydrocks" of IV,one of the sharpest and most trusted posters on IV:
Aastra Impact
The Aastra settlement is significant for a few key reasons.
1. They are paying a one time payment for past infringement and have agreed to ongoing royalty payments for future use of the patents. I expect the one time payment to be small, but that's a non-issue to me given that they have signed a deal that was agreeable to KL.
2. This shows after the Markman, the defendants are no longer united. One of the small players buckled and this is huge. It now makes all other defendants that are not Apple or Cisco potential companies that settle and license in the short-term..
3. It adds a little pressure on the USPTO with respect to the patent reexams. Clearly the patents are strong enough in Aastra's eyes that they do not see point in waiting for reexams to be finalized.
This is huge and big money will start figuring this out very soon.
VHC,
This is just the beginning,as per this poster and many others on IV.
"As I wrote in January in my message to chipper4747...
As I wrote in message #18014 back in January, "...when we do get closer to agreements being signed (litigation moving closer to resolution, LTE-A closer to becoming commercial) I wouldn't be surprised to see most of the early agreements involving the smaller players."
Today's news was perhaps a little sooner than expected, but right on target in terms of size and scope of the player involved, Aastra.
Also, for those who feel they have "missed it" or that the ship has sailed without them --- you might want to seriously reconsider that. One of my first comments about VHC on this MN was that it makes much more sense as an investment after the next agreement was announced. Over a year ago I wrote "it makes the most sense to wait until there are actual agreements in place to be invested again" (msg #7271). Although certain events occurred (such as Nortel auction, Mosaid purchase, etc.) to change my mind, I still believe the underlying logic is sound. Today's announcement of signing a license is a game-changer and most likely a big signal to wall street going forward.
The uncertainty surrounding this investment may be changing significantly."
VHC,
Rainmaker,look at this!!!!
VirnetX And Aastra Sign A Patent License Agreement
PR Newswire
DALLAS and ZEPHYR COVE, Nev., May 3, 2012
DALLAS and ZEPHYR COVE, Nev., May 3, 2012 /PRNewswire/ -- VirnetX Holding Corp. (AMEX:VHC) and Aastra USA, Inc. (the "Parties") today announced that on May 3, 2012, they signed a Patent License Agreement (the "Agreement"). Under the terms of the Agreement, VirnetX has agreed to license certain of its patents to Aastra USA, Inc., for a one-time payment to VirnetX and an ongoing reasonable royalty for all future sales through the expiration of the licensed patents as outlined in the Agreement with respect to certain current and future IP-encrypted products.
Under the terms of the Agreement, the Parties have also agreed to dismiss the patent infringement case between the Parties and their affiliates before the U.S. District Court for the Eastern District of Texas. All other aspects of the agreement were not disclosed.
"We are pleased to have come to an agreement with Aastra on terms consistent with our VirnetX IP Licensing program," said Kendall Larsen, Chief Executive Officer and Chairman of VirnetX.
"We are pleased to reach a settlement with VirnetX to resolve these matters," said John Tobia, Vice President and General Counsel, Aastra USA, Inc.
About Aastra USAAastra USA Inc. is the US business unit of Aastra Technologies Limited, a company at the forefront of the enterprise communication market. Headquartered in Concord, Ontario, Canada, Aastra develops and delivers innovative communications products and applications for businesses. For additional information on Aastra, visit our website at www.aastrausa.com.
About VirnetXVirnetX Holding Corporation is an Internet security software and technology company with patented technology for 4G LTE security. The Company's software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company's patent portfolio includes 20 U.S. and 26 international patents and over 100 pending applications. For more information, please visit www.virnetx.com.
Forward Looking Statements by VirnetX Holding CorporationStatements in this press release that are not statements of historical or current fact, including statements regarding the strength of the patent portfolio, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's patent portfolio, legal proceedings and licensing efforts. Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management's beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company; (2) the ability to capitalize on the Company's patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company's patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company's GABRIEL Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; and (7) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in Company's Annual Report on Form 10-K filed with the SEC on February 29, 2012 and in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company's ability to control or predict. Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.
Contact:
Media contacts:Robyn Thompson+1.469.365.3249pr@aastrausa.com www.twitter.com/aastra www.youtube.com/aastratv
Greg WoodVirnetX Holding Corporation775.548.1785greg_wood@virnetx.com
SOURCE VirnetX Holding Corporation
VHC,
VirnetX And Aastra Sign A Patent License Agreement
PR Newswire
DALLAS and ZEPHYR COVE, Nev., May 3, 2012
DALLAS and ZEPHYR COVE, Nev., May 3, 2012 /PRNewswire/ -- VirnetX Holding Corp. (AMEX:VHC) and Aastra USA, Inc. (the "Parties") today announced that on May 3, 2012, they signed a Patent License Agreement (the "Agreement"). Under the terms of the Agreement, VirnetX has agreed to license certain of its patents to Aastra USA, Inc., for a one-time payment to VirnetX and an ongoing reasonable royalty for all future sales through the expiration of the licensed patents as outlined in the Agreement with respect to certain current and future IP-encrypted products.
Under the terms of the Agreement, the Parties have also agreed to dismiss the patent infringement case between the Parties and their affiliates before the U.S. District Court for the Eastern District of Texas. All other aspects of the agreement were not disclosed.
"We are pleased to have come to an agreement with Aastra on terms consistent with our VirnetX IP Licensing program," said Kendall Larsen, Chief Executive Officer and Chairman of VirnetX.
"We are pleased to reach a settlement with VirnetX to resolve these matters," said John Tobia, Vice President and General Counsel, Aastra USA, Inc.
About Aastra USAAastra USA Inc. is the US business unit of Aastra Technologies Limited, a company at the forefront of the enterprise communication market. Headquartered in Concord, Ontario, Canada, Aastra develops and delivers innovative communications products and applications for businesses. For additional information on Aastra, visit our website at www.aastrausa.com.
About VirnetXVirnetX Holding Corporation is an Internet security software and technology company with patented technology for 4G LTE security. The Company's software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company's patent portfolio includes 20 U.S. and 26 international patents and over 100 pending applications. For more information, please visit www.virnetx.com.
Forward Looking Statements by VirnetX Holding CorporationStatements in this press release that are not statements of historical or current fact, including statements regarding the strength of the patent portfolio, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's patent portfolio, legal proceedings and licensing efforts. Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management's beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company; (2) the ability to capitalize on the Company's patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company's patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company's GABRIEL Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; and (7) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in Company's Annual Report on Form 10-K filed with the SEC on February 29, 2012 and in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company's ability to control or predict. Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.
Contact:
Media contacts:Robyn Thompson+1.469.365.3249pr@aastrausa.com www.twitter.com/aastra www.youtube.com/aastratv
Greg WoodVirnetX Holding Corporation775.548.1785greg_wood@virnetx.com
SOURCE VirnetX Holding Corporation
VHC,
VirnetX And Aastra Sign A Patent License Agreement
PR Newswire
DALLAS and ZEPHYR COVE, Nev., May 3, 2012
DALLAS and ZEPHYR COVE, Nev., May 3, 2012 /PRNewswire/ -- VirnetX Holding Corp. (AMEX:VHC) and Aastra USA, Inc. (the "Parties") today announced that on May 3, 2012, they signed a Patent License Agreement (the "Agreement"). Under the terms of the Agreement, VirnetX has agreed to license certain of its patents to Aastra USA, Inc., for a one-time payment to VirnetX and an ongoing reasonable royalty for all future sales through the expiration of the licensed patents as outlined in the Agreement with respect to certain current and future IP-encrypted products.
Under the terms of the Agreement, the Parties have also agreed to dismiss the patent infringement case between the Parties and their affiliates before the U.S. District Court for the Eastern District of Texas. All other aspects of the agreement were not disclosed.
"We are pleased to have come to an agreement with Aastra on terms consistent with our VirnetX IP Licensing program," said Kendall Larsen, Chief Executive Officer and Chairman of VirnetX.
"We are pleased to reach a settlement with VirnetX to resolve these matters," said John Tobia, Vice President and General Counsel, Aastra USA, Inc.
About Aastra USAAastra USA Inc. is the US business unit of Aastra Technologies Limited, a company at the forefront of the enterprise communication market. Headquartered in Concord, Ontario, Canada, Aastra develops and delivers innovative communications products and applications for businesses. For additional information on Aastra, visit our website at www.aastrausa.com.
About VirnetXVirnetX Holding Corporation is an Internet security software and technology company with patented technology for 4G LTE security. The Company's software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company's patent portfolio includes 20 U.S. and 26 international patents and over 100 pending applications. For more information, please visit www.virnetx.com.
Forward Looking Statements by VirnetX Holding CorporationStatements in this press release that are not statements of historical or current fact, including statements regarding the strength of the patent portfolio, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's patent portfolio, legal proceedings and licensing efforts. Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management's beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company; (2) the ability to capitalize on the Company's patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company's patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company's GABRIEL Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; and (7) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in Company's Annual Report on Form 10-K filed with the SEC on February 29, 2012 and in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company's ability to control or predict. Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.
Contact:
Media contacts:Robyn Thompson+1.469.365.3249pr@aastrausa.com www.twitter.com/aastra www.youtube.com/aastratv
Greg WoodVirnetX Holding Corporation775.548.1785greg_wood@virnetx.com
SOURCE VirnetX Holding Corporation